TITLE

LEUCHEMIX PROVIDES UPDATE ON CANCER TRIAL

PUB. DATE
March 2009
SOURCE
Worldwide Biotech;Mar2009, Vol. 21 Issue 3, p2
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
This article reports on an initial clinical trial conducted by CombiMatrix Corp. for its novel anticancer drug LC-1 in 2009. CombiMatrix has announced that Leuchemix provided additional information regarding the initial trial. Results so far suggest that the drug could be particularly useful in patients who have previously responded badly to conventional chemotherapy.
ACCESSION #
36633490

 

Related Articles

  • Surrogate Efficacy Endpoints in Oncology Trials. Markman, Maurie // Pharmaceutical Medicine - New Zealand;2009, Vol. 23 Issue 5/6, p283 

    There will be little debate with the statement that the single most important goal of anti-neoplastic therapy in the setting of advanced or metastatic disease is to substantially prolong overall survival (or 'cure') from the time of initial diagnosis. As a result, this objective has been...

  • Daily aspirin reduced incidence of colorectal cancer.  // Australian Journal of Pharmacy;Apr2012, Vol. 93 Issue 1103, p90 

    The article focuses on a CAPP2 trial conducted in order to evaluate the antineoplastic effects of aspirin and a resistant starch in carriers of Lynch syndrome, a major form of hereditary colorectal cancer. The study involves the random assignment of the carriers of Lynch syndrome in a two-by-two...

  • Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. Bernardi, Ronald J.; Bomgaars, Lisa; Fox, Elizabeth; Balis, Frank M.; Egorin, Merrill J.; Lagattuta, Theodore F.; Aikin, Alberta; Whitcomb, Patricia; Renbarger, Jamie; Lieberman, Frank S.; Berg, Stacey L.; Blaney, Susan M. // Cancer Chemotherapy & Pharmacology;Jul2008, Vol. 62 Issue 2, p355 

    Purpose: A phase I study of intrathecal (IT) gemcitabine was performed to define a safe dose and characterize the toxicity profile and CSF pharmacokinetics of gemcitabine and its major metabolite 2',2'-difluoro-deoxyuridine (dFdU) in patients 3 years of age and older with neoplastic...

  • CAN-FITE BIOPHARMA INITIATES CF102 TRIAL FOR LIVER CANCER.  // Worldwide Biotech;May2009, Vol. 21 Issue 5, p8 

    This article reports on the plan of Can-Fite BioPharma of Israel to conduct a I/II clinical trial with CF102 for the treatment of liver cancer in 2009. Can-Fite announced that it will start enrolling patients for the clinical trial. The company will investigate the safety and efficacy of CF102...

  • Lenalidomide plus dexamethasone demonstrates efficacy in the treatment of relapsed or refractory multiple myeloma.  // Formulary;Feb2008, Vol. 43 Issue 2, p79 

    The article reports on two studies, which demonstrate the efficacy of a combination of lenalidomide plus dexamethasone in treating relapsed or refractory multiple myeloma. Results indicated that the length of median overall survival is greater among patients in the lenalidomide group compared...

  • Bevacizumab plus paclitaxel can slow breast cancer progression but does not improve overall survival.  // Formulary;Mar2008, Vol. 43 Issue 3, p115 

    The article reports on the findings of the clinical trial regarding the efficacy of the drug bevacizumab when administered with paclitaxel in breast cancer patients. It states that the addition of bevacizumab to treatment with paclitaxel does not extend the overall survival of cancer patients....

  • Dose Escalation Methods in Phase I Cancer Clinical Trials. Le Tourneau, Christophe; Lee, J. Jack; Siu, Lillian L. // JNCI: Journal of the National Cancer Institute;5/20/2009, Vol. 101 Issue 10, p708 

    Phase I clinical trials are an essential step in the development of anticancer drugs. The main goal of these studies is to establish the recommended dose and/or schedule of new drugs or drug combinations for phase II trials. The guiding principle for dose escalation in phase I trials is to avoid...

  • A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer. Jae Jin Lee; Si-Young Kim; Hyun-Cheol Chung; Kyung-Hee Lee; Hong-Suk Song; Won-Ki Kang; Young-Seon Hong; In-Sil Choi; Young Yeul Lee; In-Sook Woo; Jin-Hyuk Choi // Cancer Chemotherapy & Pharmacology;May2009, Vol. 63 Issue 6, p1083 

    This study was conducted to evaluate the safety and efficacy of S-1 and paclitaxel combination therapy for patients with advanced gastric cancer. Eligible patients had previously untreated advanced or relapsed gastric cancer with measurable lesion(s) and an ECOG PS of 0-2. Treatment consisted of...

  • Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors. Chia-Chi Lin; Calvo, Emiliano; Papadopoulos, Kyriakos P.; Patnaik, Amita; Sarantopoulos, John; Mita, Alain C.; Preston, Glenn G.; Mita, Monica M.; Rodon, Jordi; Mays, Theresa; I.-Tien Yeh; O'Rourke, Pat; Takimoto, Chris H.; Dancey, Janet E.; Chen, Helen; Tolcher, Anthony W. // Cancer Chemotherapy & Pharmacology;May2009, Vol. 63 Issue 6, p1065 

    Complex interrelationships exist between the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) receptor pathways. EGFR activation elicits cell proliferation and increased VEGF expression. To maximally inhibit EGFR and then downstream VEGF activity, this phase...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics